Wenbing Duan
Beijing Key Laboratory Of Hematopoietic Stem Cell Transplantation
Beijing, 100044, China
Beijing, 100044, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Genetic abnormalities predict outcomes in patients with core binding factor acute myeloid leukemia.
Journal: Annals of hematology
Published: August 05, 2024
Only FLT3-ITD co-mutation did not have a deleterious effect on acute myeloid leukemia patients with NPM1 mutation, but concomitant with DNMT3A co-mutation or a < 3log reduction of MRD2 predicted poor survival.
Journal: Annals of hematology
Published: June 10, 2024
Allogeneic stem cell transplantation is still a highly curative therapy in adults with philadelphia chromosome-positive acute lymphoblastic leukaemia.
Journal: Annals of hematology
Published: November 25, 2023
A first case report of using chimeric antigen receptor T-cell immunotherapy to treat high-risk smoldering multiple myeloma.
Journal: Journal of translational internal medicine
Published: September 04, 2023
Comparison of efficacy between homoharringtonine, aclarubicin, cytarabine (HAA) and idarubicin, cytarabine (IA) regimens as induction therapy in patients with de novo core binding factor acute myeloid leukemia.
Journal: Annals of hematology
Published: July 28, 2023
Is t(11;14)(q13;q32) good or bad for newly diagnosed multiple myeloma?
Journal: Chinese medical journal
Published: February 02, 2023
COVID-19 infection in patients with haematological malignancies: A single-centre survey in the latest Omicron wave in China.
Journal: British journal of haematology
Published: January 21, 2023
Circulating Tumor DNA: Less Invasive, More Representative Method to Unveil the Genomic Landscape of Newly Diagnosed Multiple Myeloma Than Bone Marrow Aspirates.
Journal: Cancers
Published: September 02, 2022
T cell landscape and dynamics in immunoglobulin light chain amyloidosis before and after daratumumab-based therapy.
Journal: Clinical and translational medicine
Published: June 24, 2021
Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center.
Journal: Annals of hematology
Published: January 13, 2021
The loss or absence of minimal residual disease of <0·1% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis.
Journal: British journal of haematology
Published: March 02, 2020
Last Updated: 09/26/2026